Showing 951-960 of 10590 results for "".
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
https://reachmd.com/programs/cme/optimizing-raasimra-therapy-in-patients-with-heart-failure-ckd-and-hyperkalemia-a-microlearning-curriculum-approach/26750/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Precision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies
https://reachmd.com/programs/cme/precision-strikes-in-aml-navigating-the-evolving-landscape-of-targeted-therapies/48856/Explore AML treatments targeting FLT3 and KMT2A/NPM1, focusing in on molecular diagnostics, clinical data, therapy sequencing, and adverse event management.When Topicals Fail: The New IPC Consensus Every Clinician Should Know
https://reachmd.com/programs/cme/when-topicals-fail-the-new-ipc-consensus-every-clinician-should-know/39967/Review IPC’s 2025 consensus guidance on reclassifying psoriasis severity and redefining failure of topical therapies.Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
https://reachmd.com/programs/cme/chairperson-perspective-acromegaly-care-individualized-diagnosis-and-management-strategies/33027/Join us to discover the current recommendations and scientific data on the diagnosis and therapeutic management of acromegaly.Real-World Ready: Practical Tips for Community Oncologists
https://reachmd.com/programs/cme/real-world-ready-practical-tips-for-community-oncologists/36572/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityBeyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
https://reachmd.com/programs/cme/beyond-the-horizon-in-multiple-myeloma-harnessing-novel-celmod-mechanisms-for-increased-antimyeloma-activity/35916/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityChairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
https://reachmd.com/programs/cme/chairpersons-perspective-optimizing-perioperative-therapy-in-early-stage-nsclc-a-multidisciplinary-approach/34985/Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary ApproachWhy CELMoDs Matter in Myeloma
https://reachmd.com/programs/cme/why-celmods-matter-in-myeloma/36558/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityCase Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
https://reachmd.com/programs/cme/case-application-unlocking-relapsedrefractory-myeloma-with-celmods/36574/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityCase Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
https://reachmd.com/programs/cme/case-application-frontline-insightstackling-newly-diagnosed-myeloma/36573/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity